Imatinib mesylate as first‑line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: A retrospective analysis.

Simple item page
dc.contributor.authorThota, N K
dc.contributor.authorGundeti, S
dc.contributor.authorLinga, V G
dc.contributor.authorCoca, P
dc.contributor.authorTara, R P
dc.contributor.authorRaghunadharao
dc.date.accessioned2014-12-29T09:25:35Z
dc.date.available2014-12-29T09:25:35Z
dc.date.issued2014-01
dc.description.abstractINTRODUCTION: Imatinib is a bcr‑abl tyrosine kinase inhibitor which has revolutionized the treatment for chronic myeloid leukemia (CML). Even though there is much data on CML chronic phase, there is limited data on imatinib‑naïve advanced phase CML. MATERIALS AND METHODS: We retrospectively analysed 90 patients with advanced phase CML (accelerated phase [AP]: 51 and blast crisis [BC]: 39), patients who received imatinib as frontline therapy. RESULTS: The median age of presentation in CML‑AP and CML‑BC were 32 years (12‑61) and 39 years (8‑59), respectively. Imatinib at 600 mg/day was initiated within 2 weeks of diagnosis. Median time to complete hematological response in both CML‑AP and CML‑BC was 3 months (CML‑AP: 1‑9 months and CML‑BC: 1‑14 months). At 6 months 30 (59%) CML‑AP and 15 (38%) CML‑BC patients achieved major cytogenetic response (MCyR), of them 24 (47%) and 10 (25.6%) being the complete cytogenetic response, respectively. At a median follow‑up of 41 months, the median overall survival in CML‑AP was 61 months, but in CML‑BC it was 14 months. The median progression‑free survival and event‑free survival were 30 months and 23 months in CML‑AP and 14 and 12 months in CML‑BC, respectively. On univariate analysis, performance status (PS), spleen size, and MCyR predicted survival in AP, whereas in BC, platelet count, PS, and early MCyR were predictive. Non‑hematologic and hematologic adverse events were observed in 80% and 60% of patients, respectively. Dose was reduced in 10% of patients for grade IV toxicity and interrupted in 30% for grade III toxicity. CONCLUSION: Front‑line imatinib is an option in advanced phases of CML especially in CML‑AP in low‑resource countries, where stem cell transplantation and alternate TKIs are not available.en_US
dc.identifier.citationThota N K, Gundeti S, Linga V G, Coca P, Tara R P, Raghunadharao. Imatinib mesylate as first‑line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: A retrospective analysis. Indian Journal of Cancer. 2014 Jan-Mar; 51(1): 5-9.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/154271
dc.language.isoenen_US
dc.source.urihttps://www.indianjcancer.com/article.asp?issn=0019-509X;year=2014;volume=51;issue=1;spage=5;epage=9;aulast=Thotaen_US
dc.subjectAccelerated phase and blast crisisen_US
dc.subjectchronic myeloid leukemiaen_US
dc.subjectimatiniben_US
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAntineoplastic Agents --therapeutic use
dc.subject.meshBenzamides --therapeutic use
dc.subject.meshBlast Crisis --drug therapy
dc.subject.meshBlast Crisis --mortality
dc.subject.meshBlast Crisis --pathology
dc.subject.meshChild
dc.subject.meshDrug Resistance, Neoplasm --drug effects
dc.subject.meshFemale
dc.subject.meshFollow-Up Studies
dc.subject.meshHumans
dc.subject.meshLeukemia, Myelogenous, Chronic, BCR-ABL Positive --drug therapy
dc.subject.meshLeukemia, Myelogenous, Chronic, BCR-ABL Positive --mortality
dc.subject.meshLeukemia, Myelogenous, Chronic, BCR-ABL Positive --pathology
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Staging
dc.subject.meshPiperazines --therapeutic use
dc.subject.meshPrognosis
dc.subject.meshPyrimidines --therapeutic use
dc.subject.meshRemission Induction
dc.subject.meshRetrospective Study
dc.subject.meshSurvival Rate
dc.subject.meshYoung Adult
dc.titleImatinib mesylate as first‑line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: A retrospective analysis.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijc2014v51n1p5.pdf
Size:
654.25 KB
Format:
Adobe Portable Document Format
Description:
Original Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Cancer